Nuvaxovid Market Report 2026

Nuvaxovid Market Overview

• The Nuvaxovid market growth in the historic period has been driven by global covid-19 pandemic response initiatives, emergency use authorizations for vaccines • Market expansion is supported by continued demand for booster immunizations, rising focus on variant-adapted vaccines • Growth Driver: Rising Infectious Diseases And COVID-19 Prevalence Boost The Market • Market Trend: Updated Vaccine Targets Emerging COVID-19 Variants Enhancing Global Vaccination Efforts • North America was the largest region in 2025.

What Is Covered Under Nuvaxovid Market?

Nuvaxovid is a protein-based vaccine that uses recombinant spike protein from the SARS-CoV-2 virus combined with an adjuvant (Matrix-M) to enhance the immune response. It stimulates the immune system to recognize and fight the virus, protecting against COVID-19. Nuvaxovid is administered as a two-dose series and is authorized in various countries to prevent COVID-19 in individuals aged 12 and older. The main utilizations of the nuvaxovid are primary immunization, booster immunization, immunocompromised patients, elderly populations, pediatric immunization, and travel immunization. Primary immunization is the initial series of vaccine doses administered to stimulate and establish long-term immunity against specific infectious diseases. It is used by the hospitals, clinics, ambulatory care, and home care. nuvaxovid is distributed through channels such as retail pharmacies, online sales, and government programs.

What Is The Nuvaxovid Market Growth Forecast?

The growth in the forecast period can be attributed to continued demand for booster immunizations, rising focus on variant-adapted vaccines, expansion of global vaccination coverage, increasing preference for diversified vaccine technologies, strengthening of pandemic preparedness strategies. Major trends in the forecast period include increasing adoption of protein-based vaccine platforms, rising focus on adjuvant-enhanced immunogenicity, expansion of cold-chain optimized vaccine distribution, growing demand for non-mrna covid-19 vaccines, enhanced monitoring of vaccine safety and efficacy.

What Are The Drivers Of The Nuvaxovid Market?

The rising prevalence of infectious diseases is expected to drive the growth of the nuvaxovid market going forward. Infectious diseases are illnesses caused by harmful microorganisms, such as bacteria, viruses, fungi, or parasites, that spread from person to person or through the environment. The rise in infectious diseases is fueled by global travel, urbanization, climate change, antimicrobial resistance, and the emergence of new pathogens, all contributing to their growing prevalence. Nuvaxovid contributes to addressing the rise in the prevalence of infectious diseases by providing an effective vaccine to prevent COVID-19 and reduce transmission, helping to curb the spread of the virus globally. For instance, in March 2023, according to the Office for National Statistics, a UK-based government agency, COVID-19 infections increased in England, with an estimated 2.66% of the population testing positive (1 in 40 people) during the week ending 13 March 2023, while trends were uncertain in Wales (2.41%, 1 in 40), Scotland (2.59%, 1 in 40), and Northern Ireland (1.42%, 1 in 70). The infection rate rose in the North West, East Midlands, and South East, affecting age groups from 2 years to school Year 11 and those aged 50 and over, with hospital admissions for confirmed COVID-19 in England rising to 10.62 per 100,000 people by the week ending 19 March 2023, and 619 COVID-19-related deaths in the UK by the week ending 17 March 2023, up from 605 the previous week. Therefore, the rising prevalence of infectious diseases is driving the nuvaxovid industry. The increase in vaccine demand is expected to drive the growth of the nuvaxovid market going forward. Vaccines are biological substances that stimulate the immune system, enabling the body to recognize and fight specific infectious diseases. The demand for vaccines is increasing due to the rise in infectious diseases, greater public awareness of health protection, advancements in vaccine development, and the growing focus on preventive healthcare. Nuvaxovid addresses the rising vaccine demand by providing an updated solution targeting emerging COVID-19 variants, ensuring broader protection, and supporting global immunization efforts. For instance, in November 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, by October 2024, 13.7% of U.S. adults aged 18 and older had received the 2024–25 COVID-19 vaccine, while 24.5% had received the flu vaccine for the same season. Vaccination rates were highest among those aged 65 and older, with 29.1% receiving COVID-19 and 43.1% the flu vaccine. Therefore, the increase in demand for vaccines is driving the nuvaxovid industry.

Key Players In The Global Nuvaxovid Market

Major companies operating in the nuvaxovid market are Novavax Inc.

Global Nuvaxovid Market Trends and Insights

The key trend in the nuvaxovid market is developing innovative vaccine delivery systems, such as updated COVID-19 vaccines, to provide an effective solution for preventing COVID-19 and addressing emerging variants, enhancing global vaccination efforts. An updated COVID-19 vaccine is a modified version of the original vaccine designed to improve protection against newly circulating variants of the SARS-CoV-2 virus, ensuring continued effectiveness in preventing severe illness and hospitalization. For instance, in October 2024, Novavax, Inc., a US-based biotechnology company, announced that the European Commission granted marketing authorization for Novavax's updated 2024-2025 Nuvaxovid COVID-19 vaccine (recombinant, adjuvanted) for individuals aged 12 and older to prevent COVID-19 in the European Union. The updated vaccine targets the JN.1 lineage and provides cross-reactivity against several other variants. This approval is significant as it expands access to an updated vaccine formulation to address emerging COVID-19 variants and supports ongoing global vaccination efforts.

What Defines the Nuvaxovid Market?

The nuvaxovid market consists of sales of nuvaxovid multidose vial and the single dose. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nuvaxovid Market Report 2026?

The nuvaxovid market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nuvaxovid industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.